Market Insights
The global H2-receptor antagonists (H2RA) market is projected to grow at a higher CAGR within the forecast period from 2018 to 2026. H2-receptor antagonists play a very important role in preventing the secretion of gastric acid and treating duodenal ulcers, peptic ulcers, and esophageal ulcers. There is a vast range of H2RA products available in the market in the form of tablets, solutions, and forecast period from 2018 to 2026. H2-receptor antagonists play a very important role in preventing the secretion of gastric acid and treating duodenal ulcers, peptic ulcers, and esophageal ulcers. There are a vast range of H2RA products available in the market in the form of tablets, solutions, injectables, and so on, which can be easily obtained through prescriptions or over-the-counter (OTC) channels. According to the Centers for Disease Control and Prevention (CDC), every year in the United States, around 6 million individuals get affected by peptic ulcer disease (PUD).
The surge in the utilization of non-steroidal anti-inflammatory drugs (NSAIDs) due to the growing prevalence of inflammatory diseases, for example, aspirin, and growing awareness related to the better treatment options for gastroesophageal reflux disease and Zollinger-Ellison syndrome will drive the growth of the H2-receptor antagonists market during the forecast period from 2018 to 2026.
Factors driving the growth of the H2-receptor antagonist market include the rising prevalence of peptic ulcers, aggravated by sedentary lifestyles and unhealthy diets, and the growth in the smoking rate. Additionally, the easy availability of treatment medications and improved diagnostic techniques further facilitate the market’s growth. The increasing occurrence of complications related to peptic ulcers, such as bleeding and perforation, are the main considerations driving the worldwide H2-receptor antagonist market. Along with peptic ulcers, the growing prevalence of other conditions, such as esophageal ulcers and duodenal ulcers, will also drive the H2-receptor antagonist market.
The global H2-receptor antagonists market is classified as follows:
Global H2-Receptor Antagonists Market, by Product Types, 2016–2026 (US$ Mn)
- Tablets
- Solutions
- Injectable
- Others (capsule, syrup, powder for suspension)
Global H2-Receptor Antagonists Market, by Drug Class, 2016–2026 (US$ Mn)
- Cimetidine
- Famotidine
- Nizatidine
- Ranitidine
Global H2-Receptor Antagonists Market, by Geography, 2016–2026 (US$ Mn)
- North America
- Europe
- Germany
- France
- Italy
- U.K.
- Russia
- Rest of Europe
- Asia-Pacific
- India
- China
- Japan
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa
The following companies have been identified as key players in the H2-Receptor Antagonists Market:
Tocris Bioscience, GlaxoSmithKline plc, Modi Lifecare Industries Limited, Merck & Company, Inc., Apex Biotechnology Corp., Inc., Axon Medchem, Medochemie, and others
This report offers the following:
- A summary of the global market for h2-receptor antagonists
- Company profiles emphasize key information about the main players functioning in the h2-receptor antagonist market
- Highlighting every level of market category based on product approvals and existing and predicted market dynamics
- Qualitative evaluation tools such as challenges, market drivers, and future scenarios
- Competitive landscape and market share analysis are two market competition investigation tools.
- A collective overview of the industry structure
